Home / News / BioBlast® / Biosimilar Deals 2018


Biosimilars Deals 2018

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

Biogen and Samsung Bioepis close asset transfer for Biogen share increase

Biogen and Samsung Bioepis close asset transfer to increase Biogen’s share in Samsung Bioepis to 49.9%. This deal originates from the initial creation of Samsung Bioepis and the partnership between Biogen and Samsung BioLogics, in which Biogen was granted an option to increase its share in the company, expiring in mid 2018.

US-Mexico-Canada Agreement exclusivity period raises concerns

US-Mexico-Canada Agreement includes 10 year exclusivity period for biologic drugs, raising concerns that competition will be hindered to the disadvantage of consumers and health services in those regions. Currently the exclusivity period stands at 8 years in Canada and 5 years in Mexico.

BioSciences Corp and Mab-Venture announce development/commercialisation deal

Californian HQ’d BioSciences Corp & Shanghai based Mab-Venture announce a deal under which Mab-Venture will develop and manufacture biosimilars and BioSciences Corp will commercialise (through partners) those products in India, SAARC, MENA, Turkey, LatAm and Russia. The deal covers “multiple” products which have not been named.  Read more

BioBlast® Editor and Contributing Author

Naomi Pearce & Sian Hope

Naomi Pearce & Sian Hope

Editor: Naomi Pearce, Executive Lawyer, Patent Attorney & Trade Mark Attorney
Contributing Author: Sian Hope, Lawyer

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.